In vitro drug release behavior of doxorubicin, Alizarin Red S, FITC-dextran from photocross-linked dextran-methacrylate hydrogel was studied. The effects of pH of media, degree of substitution (DS) of dextran-methacrylate hydrogel, and molecular weight of model compounds on their release profiles were investigated. Each model compound was successfully incorporated into dextran-methacrylate hydrogel matrix through photo-polymerization of the hydrogel precursor. Delayed release of model compounds was observed with these hydrogels having a higher DS. Doxorubicin and Alizarin Red S showed pH-dependent release behavior because of the presence of ionizable groups in their structure. Different types of ionization of doxorubicin and Alizarin Red S resulted in more release into an acidic or alkaline media. As molecular weights of drugs increased, the total amount of released drug at the end of 240 hrs decreased significantly and reached a minimum level as the MW of drugs reached about 10,000. Release of these three model compounds followed simple Fickian diffusion at an early stage of release, i.e., cumulative release of model compounds was proportional to the square root of time. Dextran-methacrylate hydrogel effectively delayed and controlled the release of anticancer antibiotics, doxorubicin.
2. Remers, W. A.1979. The Chemistry of Antitumor Antibiotics, New York: John Wiley & Sons, 108-127.
3.
3. Jurczak, J. and Golebiowski, A.1993. Antibiotics and Antiviral Compounds, Weinheim: VCH, 352-356.
4.
4. Arcamone, F.1980. Anticancer Agents Based on Natural Product Models, New York: Academic Press, 1-41.
5.
5. Barabas, K., Sizensky, J. A. and Faulk, W. P.1992. "Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA,"J. Biol. Chem., 267:9437-9442.
6.
6. Arrington, K. A., Legendre, A. M., Tabeling, G. S. and Frazier, D. L.1994. "Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs,"Am. J. Vet. Res., 55:1587-1592.
7.
7. Boucek, R. J., Olson, R. D., Brenner, D. E., Ogunbunmi, E. M., Inui, M. and Fleischer, S.1987. "The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps,"J. Biol. Chem., 262:15851-15856.
8.
8. Matherne, C. M., Satterfield, W. C., Gasparini, A., Tonetti, M., Astroff, A. B., Schmidt, R. D., Rowe, L. D. and DeLoach, J. R.1994. "Clinical efficacy and toxicity of doxorubicin encapsulated in glutaraldehyde-treated erythrocytes administered to dogs with lymphosarcoma,"Am. J. Vet. Res., 55:847-853.
9.
9. Tonetti, M., Astroff, A. B., Satterfield, W., Flora, A. D., Benatti, U. and DeLoach, J. R.1990. "Pharmacokinetic properties of doxorubicin encapsulated in glutaraldehyde-treated canine erythrocytes,"Am. J. Vet. Res., 52:1630-1635.
10.
10. Arap, W., Pasqualini, R. and Ruoslahti, E.1998. "Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model,"Science, 279:377-379.
11.
11. Gupta, P. K. and Hung, C. T.1990. "Comparative disposition of adriamycin delivered via magnetic albumin microspheres in presence and absence of magnetic field in rats,"Life Sciences, 46:471-479.
12.
12. Ferruti, P.1979. "Synthesis and exchange reactions of biodegradable drug-binding matrices,"Makromol. Chem., 180:375-382.
13.
13. Spinney, L.1994. "Sugar-coated crystals could take gene therapy into brain,"Science, 16.
14.
14. Dan, W. and Saltzman, W. M.1992. "Dextran retention in the rat brain following release from a polymer implant,"Biotechnol. Prog., 8:527-532.
15.
15. Sidebotham, R. L.1974. Advances in Carbohydrate Chemistry and Biochemistry, New York: Academic Press, 371-383.
16.
16. Park, K., Shalaby, W. S. W. and Park, H.1993. Biodegradable Hydrogels for Drug Delivery, Lancaster, PA: Technomic Publishing Company, Inc., 85-87.
17.
17. Sery, T. W. and Hehre, E. J.1956. "Degradation of dextrans by enzymes of intestinal bacteria,"J. Bacteriology, 71:373-380.
18.
18. Dijk-Wolthuis, W. N. E. v., Hoogeboom, J. A. M., Steenbergen, M. J. v., Tsang, S. K. Y. and Hennink, W. E.1997. "Degradation and release behavior of dextran-based hydrogels,"Macromolecules, 30:4639-4645.
19.
19. Sawhney, A. S., Pathak, C. P. and Hubbell, J. A.1993. "Bioerodible hydrogels based on photopolymerized poly(ethylene glycol)-co-poly-(c(-hydroxy acid) diacrylate macromers,"Macromolecules, 26:581-587.
20.
20. Vyavahare, N. and Kohn, J.1994. "Photocrosslinked hydrogels based on copolymers of poly(ethylene glycol) and lysine,"J. Poly. Sci., Part A: Polym. Chem., 32:1271-1281.
21.
21. Graham, N. B. and McNell, M. E.1984. "Hydrogels for controlled drug delivery,"Biomaterials, 5:27-36.
22.
22. Hennink, W. E., Talsma, H., Borchert, J. C. H., Smedt, S. C. D. and Demeester, J.1996. "Controlled release of proteins from dextran hydrogels,"J. Control. Release, 39:47-55.
23.
23. Franssen, O., Vos, O. P. and Hennink, W. E.1997. "Delayed release of a model protein from enzymatically-degrading dextran hydrogels,"J. Control. Release, 44:237-245.
24.
24. Andreopoulos, F. M., Deible, C. R., Stauffer, M. T., Weber, S. G., Wagner, W. A., Beckman, E. J. and Russell, A. J.1996. "Photoscissable hydrogel synthesis via rapid photopolymerization of novel PEG-based polymers in the absence of photoinitiators,"J. Am. Chem. Soc., 118:6235-6240.
25.
25. Elisseeff, J., Anseth, K., Langer, R. and Hrkach, J.1997. "Synthesis and characterization of photocrosslinked polymers based on poly(L-lactic acid-co-L aspartic acid),"Macromolecules, 30:2182-2184.
26.
26. Kim, S.-H., Won, C.-Y. and Chu, C.-C. In Press. "Synthesis and characterization of dextran-maleic acid based hydrogel,"J. Biomed. Mater. Res.
27.
27. Kim, S.-H. and Chu, C.-C. Pending. "Synthesis and characterization of dextran-methacrylate hydrogel and its structural study by SEM,"J. Biomed. Mater. Res.
28.
28. Baker, R.1987. Controlled Release of Biologically Active Agents, New York: John Wiley & Sons, 1-105.
29.
29. Lillie, R. D.1977. H. J. Conn's Biological Stains, Baltimore: The Williams & Wilkins Company, 432-433.
30.
30. Williams Jr., T. W.1941. "Alizarin Red Sand Toluidine Blue for differentiating adult or embryonic bone and cartilage,"Stain Technology, 16:23-25.
31.
31. Sinsheimer, J. E., Jagodic, V. and Burckhalter, J. H.1974. "Fluorescein isothiocyanates: Improved synthesis and purity spectral studies,"Anal. Biochem., 57:227-231.
32.
32. Aoyagi, T., Nakamura, A., Ikeda, H., Ikeda, T., Mihara, H. and Ueno, A.1997. "Alizarin yellow-modified P-cyclodextrin as a guest-responsive absorption change sensor,"Anal. Chem., 69:659-663.
33.
33. Benthem, M. H. V. and Gillispie, G. D.1984. "Intramolecular hydrogen bonding. 4. Dual fluorescence and excited-state proton transfer in 1,5-dihydroxyanthraquinone,"J. Phys. Chem., 88:2654-2960.
34.
34. Helfferich, F.1962. Ion Exchange, New York: McGraw-Hill Book Company, Inc., 95-125.
35.
35. Sturgeon, R. J. and Schulman, S. G.1977. "Electronic absorption spectra and protolytic equilibria of doxorubicin: Direct spectrophotometric determination of microconstants,"J. Pharm. Sci., 66:958-961.
36.
36. Barthelemy-Clavey, V., Maurizot, J.-C., Dimicoli, J.-L. and Sicard, P.1974. "Self-association of daunorubicin,"FEBS Letters, 46:5-10.
37.
37. Eksborg, S.1978. "Extraction of daunorubicin and doxorubicin and their hydroxyl metabolites: self-association in aqueous solution,"J. Pharm. Sci., 67:782-785.
38.
38. Edwards, D. A., Hanes, J., Caponetti, G., Hrkach, J., Ben-Jebria, A., Eskew, M. L., Mintzes, J., Deaver, D., Lotan, N. and Langer, R.1997. "Large porous particles for pulmonary drug delivery,"Science, 276:1868-1871.
39.
39. Jones, C., Burton, M. A. and Gray, B. N.1989. "Albumin microspheres as vehicles for the sustained and controlled release of doxorubicin,"J. Pharm. Pharmacol., 41:813-816.
